Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 10/20 | 0.44 |
| ▸ | THRA | P10827 | 7/20 | 0.44 |
| ▸ | RORC | P51449 | 4/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16495821 | 1.00 | THRB (0.44) | THRBTHRARORCMAPK1HSD17B10 | |
| SCHEMBL2170309 | 0.92 | THRB (0.46) | THRBTHRARORCMAPK1HSD17B10 | |
| SCHEMBL16496217 | 0.92 | THRB (0.46) | THRBTHRARORCMAPK1HSD17B10 | |
| SCHEMBL2170941 | 0.88 | POLB (0.39) | THRBTHRAMAPK1HSD17B10LMNA | |
| SCHEMBL2170982 | 0.86 | TNFRSF1A (0.41) | THRBTHRAMAPK1HSD17B10LMNA | |
| SCHEMBL16495878 | 0.86 | TNFRSF1A (0.41) | THRBTHRAMAPK1HSD17B10LMNA | |
| SCHEMBL16496152 | 0.85 | THRB (0.46) | THRBTHRARORCMAPK1HSD17B10 | |
| SCHEMBL2172723 | 0.85 | THRB (0.46) | THRBTHRARORCMAPK1HSD17B10 | |
| SCHEMBL16496323 | 0.85 | MAPT (0.41) | THRBTHRAMAPK1HSD17B10LMNA | |
| SCHEMBL2183907 | 0.85 | MAPT (0.41) | THRBTHRAMAPK1HSD17B10LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110301200-A1 | THYROID RECEPTOR LIGANDS | CADILA HEALTHCARE LIMITED (IN) | 2011-12-08 | — | — | US | claimed |
| EP-2346814-A2 | THYROID RECEPTOR LIGANDS | Cadila Healthcare Limited (IN) | 2011-07-27 | — | — | EP | claimed |
| WO-2010049946-A2 | THYROID RECEPTOR LIGANDS | CADILA HEALTHCARE LIMITED (IN) | 2010-05-06 | — | — | WO | claimed |
| US-20110301200-A1 | THYROID RECEPTOR LIGANDS | CADILA HEALTHCARE LIMITED (IN) | 2011-12-08 | — | — | US | disclosed |
| EP-2346814-A2 | THYROID RECEPTOR LIGANDS | Cadila Healthcare Limited (IN) | 2011-07-27 | — | — | EP | disclosed |
| WO-2010049946-A2 | THYROID RECEPTOR LIGANDS | CADILA HEALTHCARE LIMITED (IN) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301200-A1 | THYROID RECEPTOR LIGANDS | TSHR, THRB, THRA | THRB 2/4885THRA 3/4885RORC 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.